Table 5.
Association between clinicopathology characteristics and molecular features (n = 231).
| Characteristic | Microsatellite Instability Status | BRAF Exon 15 | MLH1 Promoter | Probable Lynch | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MSI N = 44 |
MSS N = 187 |
p-Value 1 | Mutant N = 25 |
Wild-Type N = 206 |
p-Value 1 | Methylated N = 6 |
Unmethylated N = 225 |
p-Value 1 | No N = 199 |
Yes N = 32 |
p-Value 1 | |
| Sex | 0.4 | 0.7 | 0.7 | 0.13 | ||||||||
| Female | 20 (45.45%) | 99 (52.94%) | 14 (56.00%) | 105 (50.97%) | 4 (66.67%) | 115 (51.11%) | 107 (53.77%) | 12 (37.50%) | ||||
| Male | 24 (54.55%) | 88 (47.06%) | 11 (44.00%) | 101 (49.03%) | 2 (33.33%) | 110 (48.89%) | 92 (46.23%) | 20 (62.50%) | ||||
| Tumor Site | <0.001 *** | 0.14 | 0.047 * | 0.003 ** | ||||||||
| Left | 23 (52.27%) | 157 (83.96%) | 19 (76.00%) | 161 (78.16%) | 2 (33.33%) | 178 (79.11%) | 162 (81.41%) | 18 (56.25%) | ||||
| Right | 20 (45.45%) | 30 (16.04%) | 5 (20.00%) | 45 (21.84%) | 4 (66.67%) | 46 (20.44%) | 36 (18.09%) | 14 (43.75%) | ||||
| Unknown | 1 (2.27%) | 0 (0.00%) | 1 (4.00%) | 0 (0.00%) | 0 (0.00%) | 1 (0.44%) | 1 (0.50%) | 0 (0.00%) | ||||
| Stage | 0.4 | 0.7 | 0.7 | 0.6 | ||||||||
| I | 3 (6.82%) | 8 (4.28%) | 0 (0.00%) | 11 (5.34%) | 0 (0.00%) | 11 (4.89%) | 8 (4.02%) | 3 (9.38%) | ||||
| II | 10 (22.73%) | 56 (29.95%) | 6 (24.00%) | 60 (29.13%) | 1 (16.67%) | 65 (28.89%) | 58 (29.15%) | 8 (25.00%) | ||||
| III | 14 (31.82%) | 42 (22.46%) | 6 (24.00%) | 50 (24.27%) | 3 (50.00%) | 53 (23.56%) | 48 (24.12%) | 8 (25.00%) | ||||
| IV | 15 (34.09%) | 77 (41.18%) | 12 (48.00%) | 80 (38.83%) | 2 (33.33%) | 90 (40.00%) | 80 (40.20%) | 12 (37.50%) | ||||
| Unknown | 2 (4.55%) | 4 (2.14%) | 1 (4.00%) | 5 (2.43%) | 0 (0.00%) | 6 (2.67%) | 5 (2.51%) | 1 (3.12%) | ||||
| T Status | 0.7 | >0.9 | 0.4 | 0.6 | ||||||||
| 1 | 1 (2.27%) | 1 (0.53%) | 0 (0.00%) | 2 (0.97%) | 0 (0.00%) | 2 (0.89%) | 1 (0.50%) | 1 (3.12%) | ||||
| 2 | 4 (9.09%) | 21 (11.23%) | 3 (12.00%) | 22 (10.68%) | 0 (0.00%) | 25 (11.11%) | 22 (11.06%) | 3 (9.38%) | ||||
| 3 | 30 (68.18%) | 120 (64.17%) | 16 (64.00%) | 134 (65.05%) | 6 (100.00%) | 144 (64.00%) | 130 (65.33%) | 20 (62.50%) | ||||
| 4 | 9 (20.45%) | 44 (23.53%) | 6 (24.00%) | 47 (22.82%) | 0 (0.00%) | 53 (23.56%) | 45 (22.61%) | 8 (25.00%) | ||||
| x | 0 (0.00%) | 1 (0.53%) | 0 (0.00%) | 1 (0.49%) | 0 (0.00%) | 1 (0.44%) | 1 (0.50%) | 0 (0.00%) | ||||
| N Status | 0.8 | 0.7 | 0.3 | 0.8 | ||||||||
| 0 | 21 (47.73%) | 94 (50.27%) | 11 (44.00%) | 104 (50.49%) | 1 (16.67%) | 114 (50.67%) | 97 (48.74%) | 18 (56.25%) | ||||
| 1 | 15 (34.09%) | 65 (34.76%) | 10 (40.00%) | 70 (33.98%) | 4 (66.67%) | 76 (33.78%) | 70 (35.18%) | 10 (31.25%) | ||||
| 2 | 6 (13.64%) | 24 (12.83%) | 3 (12.00%) | 27 (13.11%) | 1 (16.67%) | 29 (12.89%) | 27 (13.57%) | 3 (9.38%) | ||||
| x | 2 (4.55%) | 4 (2.14%) | 1 (4.00%) | 5 (2.43%) | 0 (0.00%) | 6 (2.67%) | 5 (2.51%) | 1 (3.12%) | ||||
| Metastatic Status | 0.4 | 0.4 | >0.9 | >0.9 | ||||||||
| 0 | 27 (61.36%) | 107 (57.22%) | 12 (48.00%) | 122 (59.22%) | 4 (66.67%) | 130 (57.78%) | 115 (57.79%) | 19 (59.38%) | ||||
| 1 | 15 (34.09%) | 76 (40.64%) | 12 (48.00%) | 79 (38.35%) | 2 (33.33%) | 89 (39.56%) | 79 (39.70%) | 12 (37.50%) | ||||
| x | 2 (4.55%) | 4 (2.14%) | 1 (4.00%) | 5 (2.43%) | 0 (0.00%) | 6 (2.67%) | 5 (2.51%) | 1 (3.12%) | ||||
| Histological Grading | 0.003 ** | 0.8 | 0.004 ** | 0.14 | ||||||||
| 1 | 12 (27.27%) | 91 (48.66%) | 10 (40.00%) | 93 (45.15%) | 2 (33.33%) | 101 (44.89%) | 94 (47.24%) | 9 (28.12%) | ||||
| 2 | 18 (40.91%) | 73 (39.04%) | 10 (40.00%) | 81 (39.32%) | 0 (0.00%) | 91 (40.44%) | 76 (38.19%) | 15 (46.88%) | ||||
| 3 | 14 (31.82%) | 18 (9.63%) | 5 (20.00%) | 27 (13.11%) | 3 (50.00%) | 29 (12.89%) | 24 (12.06%) | 8 (25.00%) | ||||
| 4 | 0 (0.00%) | 2 (1.07%) | 0 (0.00%) | 2 (0.97%) | 1 (16.67%) | 1 (0.44%) | 2 (1.01%) | 0 (0.00%) | ||||
| Unknown | 0 (0.00%) | 3 (1.60%) | 0 (0.00%) | 3 (1.46%) | 0 (0.00%) | 3 (1.33%) | 3 (1.51%) | 0 (0.00%) | ||||
| Lymphovascular Status | 0.3 | 0.8 | 0.7 | 0.3 | ||||||||
| 0 | 11 (25.00%) | 40 (21.39%) | 4 (16.00%) | 47 (22.82%) | 2 (33.33%) | 49 (21.78%) | 42 (21.11%) | 9 (28.12%) | ||||
| 1 | 14 (31.82%) | 44 (23.53%) | 6 (24.00%) | 52 (25.24%) | 1 (16.67%) | 57 (25.33%) | 48 (24.12%) | 10 (31.25%) | ||||
| Unknown | 19 (43.18%) | 103 (55.08%) | 15 (60.00%) | 107 (51.94%) | 3 (50.00%) | 119 (52.89%) | 109 (54.77%) | 13 (40.62%) | ||||
| Pathological Morphology | 0.049 * | >0.9 | >0.9 | 0.020 * | ||||||||
| Adenocarcinoma | 41 (93.18%) | 185 (98.93%) | 25 (100.00%) | 201 (97.57%) | 6 (100.00%) | 220 (97.78%) | 197 (98.99%) | 29 (90.62%) | ||||
| Mucinous Carcinoma | 3 (6.82%) | 2 (1.07%) | 0 (0.00%) | 5 (2.43%) | 0 (0.00%) | 5 (2.22%) | 2 (1.01%) | 3 (9.38%) | ||||
| TILs | 0.4 | 0.7 | 0.14 | 0.12 | ||||||||
| Low | 10 (22.73%) | 32 (17.11%) | 3 (12.00%) | 39 (18.93%) | 2 (33.33%) | 40 (17.78%) | 34 (17.09%) | 8 (25.00%) | ||||
| Medium | 15 (34.09%) | 59 (31.55%) | 7 (28.00%) | 67 (32.52%) | 0 (0.00%) | 74 (32.89%) | 61 (30.65%) | 13 (40.62%) | ||||
| High | 10 (22.73%) | 66 (35.29%) | 11 (44.00%) | 65 (31.55%) | 2 (33.33%) | 74 (32.89%) | 71 (35.68%) | 5 (15.62%) | ||||
| Unknown | 9 (20.45%) | 30 (16.04%) | 4 (16.00%) | 35 (16.99%) | 2 (33.33%) | 37 (16.44%) | 33 (16.58%) | 6 (18.75%) | ||||
| Hemoglobin level (g/dL) | 0.044 * | 0.8 | 0.12 | 0.010 ** | ||||||||
| <10 | 10 (22.73%) | 17 (9.09%) | 2 (8.00%) | 25 (12.14%) | 1 (16.67%) | 26 (11.56%) | 18 (9.05%) | 9 (28.12%) | ||||
| ≥10 | 33 (75.00%) | 163 (87.17%) | 22 (88.00%) | 174 (84.47%) | 4 (66.67%) | 192 (85.33%) | 173 (86.93%) | 23 (71.88%) | ||||
| Unknown | 1 (2.27%) | 7 (3.74%) | 1 (4.00%) | 7 (3.40%) | 1 (16.67%) | 7 (3.11%) | 8 (4.02%) | 0 (0.00%) | ||||
| Serum albumin (g/dL) | 0.4 | 0.9 | 0.3 | 0.9 | ||||||||
| <3.5 | 16 (36.36%) | 82 (43.85%) | 10 (40.00%) | 88 (42.72%) | 3 (50.00%) | 95 (42.22%) | 85 (42.71%) | 13 (40.62%) | ||||
| >3.5 | 11 (25.00%) | 53 (28.34%) | 8 (32.00%) | 56 (27.18%) | 0 (0.00%) | 64 (28.44%) | 56 (28.14%) | 8 (25.00%) | ||||
| Unknown | 17 (38.64%) | 52 (27.81%) | 7 (28.00%) | 62 (30.10%) | 3 (50.00%) | 66 (29.33%) | 58 (29.15%) | 11 (34.38%) | ||||
| ECOG | 0.043 * | 0.2 | 0.5 | 0.010 ** | ||||||||
| ECOG 0–1 | 24 (54.55%) | 123 (65.78%) | 18 (72.00%) | 129 (62.62%) | 4 (66.67%) | 143 (63.56%) | 130 (65.33%) | 17 (53.12%) | ||||
| ECOG 2 | 12 (27.27%) | 24 (12.83%) | 1 (4.00%) | 35 (16.99%) | 0 (0.00%) | 36 (16.00%) | 25 (12.56%) | 11 (34.38%) | ||||
| ECOG 3–4 | 1 (2.27%) | 18 (9.63%) | 1 (4.00%) | 18 (8.74%) | 1 (16.67%) | 18 (8.00%) | 19 (9.55%) | 0 (0.00%) | ||||
| Unknown | 7 (15.91%) | 22 (11.76%) | 5 (20.00%) | 24 (11.65%) | 1 (16.67%) | 28 (12.44%) | 25 (12.56%) | 4 (12.50%) | ||||
| BMI (kg/m2) | 0.2 | 0.4 | 0.4 | 0.2 | ||||||||
| <18.5 | 19 (43.18%) | 52 (27.81%) | 6 (24.00%) | 65 (31.55%) | 4 (66.67%) | 67 (29.78%) | 57 (28.64%) | 14 (43.75%) | ||||
| 18.5–22.9 | 16 (36.36%) | 74 (39.57%) | 14 (56.00%) | 76 (36.89%) | 1 (16.67%) | 89 (39.56%) | 79 (39.70%) | 11 (34.38%) | ||||
| 23–24.9 | 6 (13.64%) | 25 (13.37%) | 3 (12.00%) | 28 (13.59%) | 0 (0.00%) | 31 (13.78%) | 26 (13.07%) | 5 (15.62%) | ||||
| ≥25 | 2 (4.55%) | 28 (14.97%) | 1 (4.00%) | 29 (14.08%) | 1 (16.67%) | 29 (12.89%) | 29 (14.57%) | 1 (3.12%) | ||||
| Unknown | 1 (2.27%) | 8 (4.28%) | 1 (4.00%) | 8 (3.88%) | 0 (0.00%) | 9 (4.00%) | 8 (4.02%) | 1 (3.12%) | ||||
1 Fisher’s exact test; * p < 0.05; ** p < 0.01; *** p < 0.001.